Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024530 (malaria)
 44,886 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Eighty cases of fever of undetermined origin seen at Dallas VAMC from 1979 to 1985 were analyzed. Infectious etiology was the cause in one half, with equal numbers of localized infections or systemic infections. In contrast to older series, viral infections were frequently seen, but tuberculosis and malaria were less commonly noted. Solid tumors were the most frequently diagnosed non-infectious cause of fever. Fevers secondary to malignancy commonly responded to non-steroidal anti-inflammatory agents. Patterns of illness were helpful in defining certain diseases such as adult Still's disease and polymyalgia rheumatica. Diagnostic tests of value are discussed.
 ...
PMID:Fever of undetermined origin: not what it used to be. 371 5

Eight hundred Jordanians with liver enlargement were studied: 369 (46%) were males and 431 (54%) females. Ages ranged between 13 and 85 years, with a mean of 47.4%: 766 cases demonstrated a single pathological process while 34 cases showed two or more processes. The most significant findings were: congestion secondary to cardiac failure in 323 cases (38.5%); inflammatory and parasitic processes in 192 cases (22.9%), including acute hepatitis (81 cases), hydatid cyst (63 cases), chronic hepatitis (27 cases), liver abscess (19 cases), brucellosis (one case) and malaria (one case); malignancy in 164 cases (19.6%); liver cirrhosis in 80 cases (9.5%); fatty metamorphosis in 47 cases (5.6%); metabolic and genetic disease in 11 cases (1.3%); miscellaneous conditions in nine cases (1.1%); and 15 apparently normal individuals (1.8%). Cardiac failure was the most frequent cause of hepatomegaly in this sample of Jordanians. Inflammatory processes were the second major cause, followed by malignancy and cirrhosis of the liver.
 ...
PMID:Patterns of hepatomegaly in Jordanians: a prospective study of 800 cases. 407 96

The clinical picture and local epidemiology in 65 cases of Burkitt's lymphoma seen in Ilesha, Western Nigeria, over a 16-year period is presented. Incidence figures have been calculated and comparison made with other Nigerian and East African reports. Ilesha is the centre of a high tumour density area. A changing pattern of presentation over the years has evolved. Its possible relationship to the treatment of malaria and immunization facilities is suggested and discussed.
Br J Cancer 1971 Mar
PMID:Burkitt's lymphoma in Ilesha, Western Nigeria. 558 2

Epstein-Barr virus (EBV), although not an indispensable factor for the development of Burkitt lymphoma, is apparently associated with the 20-fold higher incidence of the disease in Equatorial Africa compared to the incidence in other parts of the world. To determine whether different EBV subtypes are associated with the appearance of the malignant phenotype, we have compared the EBV genomes carried in the Burkitt tumor cells with those carried in the nonmalignant lymphoblastoid cells from the same individuals. From three patients with EBV -associated Burkitt lymphoma, tumor cell lines as well as spontaneously established lymphoblastoid cell lines representing the nonmalignant counterparts were obtained. The viral DNA in these cell lines was analyzed by Southern blot hybridization, using a set of cloned EBV DNA fragments as probes that recognize polymorphic regions in the viral genome. Using a number of different polymorphic markers to distinguish one isolate from another, the virus genome found in the tumor cells could also be identified in the nonmalignant cells of the same patient. In one case, in which two independent lymphoblastoid cell lines were established, evidence was obtained that this patient was infected by at least two distinct EBV subtypes. These results strongly suggest that in Burkitt lymphoma, the risk associated with EBV is related to cofactors such as chronic malaria and the mode of infection rather than to peculiar viral subtypes. The situation seems to be totally different from papillomavirus-associated diseases, in which the risk of progression to malignancy appears to be associated with particular viral strains.
 ...
PMID:No evidence for differences in the Epstein-Barr virus genome carried in Burkitt lymphoma cells and nonmalignant lymphoblastoid cells from the same patients. 608 53

The prevalence of antibodies against the newly described human T-cell lymphoma virus, type I (HTLV-I) in two communities in Ghana, West Africa, is described. There was no difference by community (urban, 3.6% and rural, 4.0%). Prevalence increased with age, being 5.9% among persons greater than 10 years old, but did not differ by sex. There was no difference when data were analysed by housing status or crowding. Non-confirmed reactions in the assay system were frequent and correlated with both prevalence and titer of antibody against malaria. Possible explanations include vector-borne transmission like that of malaria, but the relationship is more probably due to a polyclonal stimulation of B cells, enhancing the potential for detecting reactivity in the assay. Because assay systems vary and because most laboratories do not routinely use a confirmation assay, results presented by different groups must be interpreted cautiously.
Int J Cancer 1984 Aug 15
PMID:Type-I HTLV antibody in urban and rural Ghana, West Africa. 608 2

The relationship between viruses and naturally occurring cancers, such as hepatocellular carcinoma and genital cancers, is of great importance to Africa. On the other hand, lymphomas, leukaemias and immunodeficiencies, although of less immediate public health importance, constitute an area of outstanding interest for research and their association with the Epstein-Barr virus (EBV) and the newly discovered human retroviruses merits world-wide attention. EBV-related malignancies in Africa include both Burkitt's lymphoma (BL) and nasopharyngeal carcinoma (NPC). Whether X-linked polyclonal lymphoproliferations exist in Africa remains an open question. The interrelationship between EBV, holoendemic malaria and genetic factors (oncogenes) has been deciphered in recent years, to make BL a kind of Rosetta stone for the understanding of multistage carcinogenesis. Although the role of EBV in the causation of NPC is not well understood, the viral capsid antigen (VCA) IgA test already allows both early detection of NPC in high-incidence areas and differential diagnosis in low-incidence areas. The question whether an EBV vaccine would be of value in African countries, in relation to EBV-associated malignancies, remains an open one. The diseases associated with the recently discovered human retroviruses (human T-lymphocyte leukaemia viruses: HTLVs) represent a new area for both research and public health assessment. Limited information is available today on the geographical distribution, age prevalence and association with disease in Africa of the different members of the retrovirus family (HTLV-1, HTLV-2, LAV/HTLV-3). The proportion of HTLV-related T-cell malignancies in different parts of Africa as well as the importance of immunodeficiencies caused by the different members of the retrovirus family remain to be determined. Typical acquired immunodeficiency syndrome (AIDS) appears to exist in Central Africa, especially Zaire, and HTLVs could be of public health importance if they cause severe forms of viral, bacterial or parasitic diseases through impairment of cell-mediated immunity. Africa, is and will long remain a continent of crucial importance with regard to the role of viruses in human malignancies and especially in haematopoietic proliferative disorders.
 ...
PMID:Virus-associated lymphomas, leukaemias and immunodeficiencies in Africa. 610 Feb 86

Epstein-Barr virus genome-positive Burkitt's lymphoma is endemic in Africa and Papua New Guinea and in both countries the tumour is restricted to regions with holoendemic malaria. The present work has compared groups of healthy indigenous individuals living in malarious and non-malarious regions of Papua New Guinea for Epstein-Barr virus-specific T-cell-mediated immunity using the in vitro regression assay. Residents of the malarious region (55 tested), when compared with either residents of the non-malarious area (35 tested) or Caucasian controls (27 tested) showed a significant (p less than 0.0001) impairment of virus-specific T-cell immunity but no obvious disturbance (p greater than 0.05) of anti-viral antibody titres. These results may be important in explaining the postulated role of malarial infection as a co-factor in the pathogenesis of Burkitt's lymphoma.
Int J Cancer 1983 Jun 15
PMID:A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. 630 50

The use of liposomes has recently been the subject of considerable attention as a promising and versatile approach to drug delivery. Particularly intriguing is the possibility of targeting liposomes to specific areas of the body such as tumors or sites of inflammation or parasitic invasion for either local accumulation or release of associated drugs. This review focuses mainly on recent in vivo work having clinical potential. An extensive discussion of liposome preparation and entrapment of drugs for controlled release in vivo is also included. The stability of liposomes in biological fluids is a major problem. The mode of administration, either intraperitoneal, subcutaneous, local, oral, or respiratory, is closely related to the life of the liposomes in vivo. Following in vivo administration the lifetime of a liposome is critically dependent on its composition, size, and charge. Liposome toxicity appears to be minimal, but should be considered when administering liposomes to patients. Tissues such as the liver, spleen, and lungs, because of macrophage ingestion of liposomes, become potential sites of drug toxicity. The use of liposomes to deliver antiparasitic drugs in the treatment of malaria and leishmaniasis is promoting; so it is the use of surfactant-carrying liposomes in the treatment of respiratory distress syndrome in premature babies. Recent cancer studies utilizing liposomes both in vivo and in vitro have shown promise. In tumor-bearing animals a liposome drug delivery system has caused a regression, delayed tumor growth, and increased survival time. Although the clinical use of liposomes is only in its infancy, its potential in future therapy appears promising.
 ...
PMID:Clinical prospects for liposomes. 704 23

Pyrimethamine, a 2,4-diaminopyrimidine useful in the treatment of malaria and toxoplasmosis, was found to enhance antibody and delayed-type hypersensitivity responses to sheep red cells in mice. The immunodepression of tumour-bearing mice was also reversed by pyrimethamine. This drug may prove useful as a general immunostimulant in clinical situations where the immune system has been compromised by cancer or other debilitating illnesses.
 ...
PMID:Immunopotentiation by pyrimethamine in the mouse. 738 92

The efficacy and toxicity aspects of the iron and aluminium chelating drugs desferrioxamine and deferiprone (L1, 1,2-dimethyl-3-hydroxypyrid-4-one), have been compared. Major emphasis was given in the use of these two and also of other chelators in conditions of iron overload, imbalance and toxicity, as well as the incidence and possible causes of toxic side effects in both animals and humans. The chemical basis of chelation and the interaction of these chelators with the iron pools are discussed within the context of clinical application in iron overload and other conditions such as renal dialysis, rheumatoid arthritis, cancer, heart disease, malaria, etc. The design and development of new orally active alpha-ketohydroxypyridine and other chelators are considered and compared with 14 other chelators which have been previously tested in man for the removal of iron, most of which, however, were later abandoned because of low efficacy or major toxicity. The design of new therapeutic protocols based on the pharmacological, toxicological and metabolic transformation properties of the chelating drugs is also being considered, within the context of maximising their efficacy and minimising their toxicity. Overall, oral deferiprone appears to be as effective as s.c. desferrioxamine in the removal of iron and aluminium in man and to have a similar but different toxicity profile from desferrioxamine in both animals and man. The low cost and oral activity of deferiprone will make it the drug of choice for the vast majority of patients, who are not currently being chelated either because they cannot afford the high cost of desferrioxamine therapy or are not complying or have toxic side effects with its s.c. administration.
 ...
PMID:Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. 748 75


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>